Charles River has announced its intention to acquire non-clinical CRO MPI Research for $800m. This follows a string of acquisitions within the Integrated Drug Discovery Services (IDDS) Space at the start of 2018, including Spectris Plc's acquisition of Manchester-based Concept Life Sciences, Charles River's acquisition of Bristol-based KWS Biotest and Eurofins' acquisition of Chelmsford-based CRO Selcia.

For a wider discussion of what's driving interest in this area, particularly in the UK, see our discussion with PharmaField from earlier this month: